spacer
home > epc > spring 2017 > risky business
PUBLICATIONS
European Pharmaceutical Contractor

Risky Business

The globalisation of clinical trials and speciality pharmaceutical commercialisation, along with the rise of complex biologicalbased drug therapies, presents a host of opportunities for manufacturers. However, today’s mobile supply chain also comes with substantial risks. If overlooked, it can leave manufacturers, investors and an industry worth approximately $1.1 trillion exposed to potentially significant losses.

Managing the transportation of biopharmaceutical logistics cost almost $79 billion in 2016, with temperature-controlled products accounting for nearly $13 billion, according to Pharmaceutical Commerce’s annual Biopharma Cold Chain Sourcebook. With a growth rate of 8-9% year-on-year, spending on temperature-controlled logistics is predicted to rise to almost $17 billion by 2020, and the non-cold chain is estimated at $77 billion.

Such expense necessitates the identification and qualification of investment to mitigate mounting risks.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Nils Markmann is Vice President of Global Operations at World Courier and is responsible for the daily management of their global operation in terms of networkwide implementation and adherence to global standards, as well as for ensuring consistent operational excellence throughout the company’s 140 offices. Formerly General Manager of Operations for World Courier Germany, Nils has been with the company since 1995.
spacer
Nils Markmann
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Horizon Discovery and Fulcrum Therapeutics Form Collaboration for Novel CRISPR-Based Target Discovery in Genetic Diseases

The collaboration will utilize Horizon’s world-leading CRISPR-based screening platform to identify novel targets for regulating gene expression.
More info >>

White Papers

Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences

Myoderm

Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
More info >>

 
Industry Events

9th Global Drug Delivery & Formulation Summit

12-14 March 2018, Maritim proArte Hotel Berlin

The DDF Summit brings the most interesting studies and exciting technologies to you. This year there will be 4 dedicated streams focusing on Small Molecules, Biologics, Technology & Innovation and for the first-time Device Development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement